Biomanufacturing Services

Just-Evotec Biologics produces biopharmaceutical drug substance for its clients to support early-phase and late-phase clinical trials with its continuous manufacturing platform. Our experts are experienced in the conversion of existing fed-batch processes to our platform irrespective of the clinical stage. Our J.POD biomanufacturing facilities are designed to deliver biologics drug substance for first-in-human clinical trials all the way through to commercial production.

We manufacture antibody and antibody-related biotherapeutics for first-in-human and early-stage clinical trials in our continuous manufacturing platform. Performing early-stage clinical manufacturing with a continuous bioprocess allows partners to avoid switching from fed-batch to continuous production during their clinical journey and allows them to take advantage of lower cost of goods, greater agility and lower risk during late-stage development.

We possess the capability to provide support for late-stage clinical programs, regardless of whether an intensified process has been developed beforehand. By leveraging existing cell lines and transitioning from fed-batch to perfusion and fully continuous modes, we mitigate the scaling-up risks while reaping the benefits of lower commercial COGS and a more adaptable supply chain.

Existing commercial biotherapeutic products currently manufactured with a fed-batch process may be facing low productivity/high COGS challenges which can also be correlated to supply chain bottlenecks. We can develop intensified and fully continuous process for existing commercial molecules facing a COGS challenge or requiring larger supply capacity.

Continuous manufacturing emerges as the ideal solution for molecules, especially those with uncertain future indications or potentially facing increasing mass demand over time, offering unparalleled flexibility to meet evolving needs.